107 results
The primary aim of the phase I part of this study is to establish the safety profile and to determine the maximum tolerated dose of capecitabine combined with Re-188-HEDP.The primary aim of the phase II part of this study is to obtain insight in the…
The primary objective is to determine if the incorporation of Multimodality MRI including MRGB within the Prostate cancer Research International for Active Surveillance (PRIAS) study for low-risk low volume prostate cancer leads to a higher number…
To determine the diagnostic accuracy of multimodality MRI in detecting locally recurrent prostate cancer two years after treatment with external beam radiation therapy.
To objectify and quantify patients ano-rectal complaints to identify the exact pathophysiology and involved anatomic structures. Following this, irradiation techniques can be developed or modified to selectively spare the abovementioned structures,…
The following objectives have been defined for PROCABIO:1. Integration of biomarkers in an updated and improved model for the prediction of indolent prostate cancer.2. Integration of biomarkers in the development of guidelines for efficient…
To prove the diagnostic accuracy of 3T multi-modality MR imaging (high resolution T2-weighted MRI, DCE-MRI, MRSI and DWI techniques) in distinguishing carcinoma from other prostate tissue. The gold standard for distinguishing the tissue types is the…
To quantify the motion of the seminal vesicles.
The purpose of our study is to prospectively establish in vivo in patients proof of principle for the RUNMC MR imaging-compatible robotic system designed for image-guided prostatic needle intervention.
To determine the performance characteristics (specificity, sensitivity, and positive and negative predictive values) of the PCA3 Assay using prostate biopsy as the reference method in men who are scheduled for a repeat prostate biopsy after a…
Primary ObjectiveTo establish a prospective cohort of patients undergoing radiotherapy for breast, prostate or lung cancers following local regimens and collecting standardised radiotherapy toxicity data, non genetic risk factor data and samples for…
The primary objective is to determine the optimal pharmacokinetic model of 68Ga-PSMA PET/CT, so 68Ga-PSMA PET/CT results can be quantified in prostate cancer.The secondary objectives are to determine whether the optimal kinetic model of 68Ga-PSMA…
Primary Objective: To assess the detection rate of 18 F-FDHT PET/CT in men with recurrent prostate cancer after radiotherapy who are candidates for local salvage treatment.Secondary Objective(s): To assess the detection rate and accuracy of 18 F-…
To validate two novel genomic biomarkers that provide information with respect to the presence of PCa, disease aggressiveness, and progression towards recurrent and metastatic disease.
The proposed research combines two emerging technologies, Cerenkov Luminescence Imaging (CLI) and Gallium-68 PSMA (68Ga-PSMA), in order to assess surgical margins during prostate cancer surgery. CLI involves imaging of a faint light emitted from…
To analyse the safety of oestradiol in the setting of endocrine treatment for locally extended prostate cancer adjuvant to radiotherapy.
Primary objective:- To assess the efficacy of niraparib in subjects with measurable mCRPC and who have either biallelic DNA-repair anomalies in BRCA (BRCA 1 and BRCA 2 or germline BRCA. Secondary objectives:- To assess the efficacy of niraparib in…
Primary objective: to improve participants* quality of life, as measured by the SF-12 general health domain, by actively engaging in a prostate cancer diet. Secondary objectives: - To improve participants* feeling of being in control of their…
The primary objective of this study is to determine histological ablative efficacy by absence of vital (tumour) cells in the treated prostate zone with (multi)fibre setup in men with PCa scheduled for radical prostatectomy. The secondary objectives…
This study has been transitioned to CTIS with ID 2023-509881-39-00 check the CTIS register for the current data. The aim of this study is to evaluate the difference in the fraction of patients that have disease progression within 6 months after…
The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best supportive/best standard of care versus patients treated with best supportive/…